Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot DOI Open Access
Tuğbanur Tezvergil,

Ismini Kourouni,

Adrien E Costantini

et al.

Breathe, Journal Year: 2024, Volume and Issue: 20(2), P. 240039 - 240039

Published: June 1, 2024

Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy decided based on tumour-biological features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind treatment proposed, which immunotherapy-based or targeted therapies are considered the standards care in 2024. Oligometastatic NSCLC represents specific concept during biological spectrum from localised to disease only limited number sites can be documented. Based this assumption, prospective few randomised phase II studies have been performed, suggested that adding local ablative one new option selected stage NSCLC. The European Organisation Research Treatment Cancer (EORTC) Society Radiotherapy Oncology (ESTRO) supported efforts define oligometastatic unify semantics within thoracic oncology community. This article summarises currently available data emphasises questions perspectives cohorts.

Language: Английский

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3 DOI
Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 42(11), P. e23 - e43

Published: Feb. 28, 2024

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described ASCO Guidelines Methodology Manual . follow Conflict of Interest Policy Implementation Clinical Practice and updates not intended to substitute independent professional judgment treating provider do account individual variation among patients. See complete disclaimer Appendix 1 2 more. Updates published regularly can be found at https://ascopubs.org/nsclc-non-da-living-guideline PURPOSE To provide evidence-based recommendations patients stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This living guideline offers continually based an ongoing systematic review randomized trials (RCTs), latest time frame spanning February October 2023. An Expert Panel medical oncology, pulmonary, community research methodology, advocacy experts were convened. The search included reviews, meta-analyses, controlled trials. Outcomes interest include efficacy safety. members used available informal consensus develop recommendations. RESULTS consolidates all previous reflects body informing this topic. Ten new RCTs identified date. RECOMMENDATIONS Evidence-based address first, second, subsequent treatment options Additional information is www.asco.org/living-guidelines

Language: Английский

Citations

28
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer DOI Open Access
Kwun M. Fong, Adam Rosenthal,

Dorothy J. Giroux

et al.

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(5), P. 786 - 802

Published: Feb. 4, 2024

Language: Английский

Citations

26
Advances of PET/CT in Target Delineation of Lung Cancer Before Radiation Therapy DOI

Cedric Richlitzki,

Farkhad Manapov,

Adrien Holzgreve

et al.

Seminars in Nuclear Medicine, Journal Year: 2025, Volume and Issue: 55(2), P. 190 - 201

Published: March 1, 2025

Language: Английский

Citations

1
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication DOI Creative Commons
Margarita Kirienko, Fabrizia Gelardi, Francesco Fiz

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 11, 2024

Language: Английский

Citations

6
Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome DOI Creative Commons
Marcel Wiesweg,

Claudia Küter,

Johannes Schnorbach

et al.

International Journal of Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 25, 2024

Abstract Oligometastatic (OMD) non‐small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches lacking, in particular respect to integration immunotherapy. This real‐world study identified 218 patients OMD NSCLC (2004–2023, prespecified criteria: ≤5 metastases ≤2 organ systems) from three major German comprehensive centers. Most had one (72.5%) or two (17.4%) metastatic lesions single (89.9%) system. Overall survival (OS) was significantly longer lesion (HR 0.54, p = .003), female gender 0.4, < .001). Median OS full cohort 27.8 months, 29% at 5 years. Patients who completed LAT all sites, typically excluding early progression, median 34.4 months (37.7% 5‐year rate) recurrence‐free (RFS) 10.9 (13.3% years). In those patients, as part first‐line associated doubling RFS (12.3 vs. 6.4 Despite limited follow‐up receiving chemo‐immunotherapy (EU approval 2018/2019), greatly improved by adding checkpoint inhibitors chemotherapy 0.44, .008, 2‐year 51.4% 15.1%). conclusion, benefitted multimodality integrating ablation sites. A substantial proportion achieved extended OS, suggesting potential for cure that can be further augmented addition

Language: Английский

Citations

5
Recent developments in the field of radiotherapy for the management of lung cancer DOI Creative Commons
Katsuyuki Shirai, Shuri Aoki,

Masashi Endo

et al.

Japanese Journal of Radiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 24, 2024

Abstract Lung cancer has a poor prognosis, and further improvements in outcomes are needed. Radiotherapy plays an important role the treatment of unresectable lung cancer, there have been recent developments field radiotherapy for management cancer. However, to date, few reviews on improvement associated with high precision Thus, this review aimed summarize techniques indicate future directions use Stereotactic body (SBRT) stage I reported improve local control rates without severe adverse events, such as radiation pneumonitis. For locally advanced combination chemoradiotherapy adjuvant immune checkpoint inhibitors dramatically improves outcomes, intensity-modulated (IMRT) enables safer therapy less frequent Particle beam therapy, carbon-ion proton administered medical care patients Since 2024, it covered under insurance early tumors ≤ 5 cm size Japan. In addition chemotherapy, ablative oligometastatic IV A particular problem is that target location changes respiratory motion, various physical methods used motion. Recently, coronavirus disease had major impact treatment, during situations, pandemic, must be performed carefully. To necessary fully utilize evolving modalities, expected increase.

Language: Английский

Citations

4
Impact of immune checkpoint inhibitors and local radical treatment on survival outcomes in synchronous oligometastatic NSCLC DOI Creative Commons
Mandy Jongbloed, Valentina Bartolomeo,

Martina Bortolot

et al.

JTO Clinical and Research Reports, Journal Year: 2025, Volume and Issue: 6(3), P. 100790 - 100790

Published: Jan. 8, 2025

The impact of an immune checkpoint inhibitor (ICI)-based systemic treatment strategy with or without local radical (LRT) on outcomes for patients NSCLC and synchronous oligometastatic disease (sOMD) is unknown. Multicenter retrospective study including adequately staged patients, sOMD (maximum five metastases in three organs [European Organization Research Treatment Cancer definition]) between January 1, 2015 December 31, 2022, treated a first-line ICI-based versus chemotherapy-only regimen. Primary end points were progression-free survival overall (OS) strategy. Subgroup analyses performed who deemed candidates LRT the multidisciplinary meeting those proceeding to LRT. A total 416 included, chemotherapy-ICI (n = 138) 278), 319 out by meetings LRT, whereas 192 (60%) proceeded median OS was significantly longer compared group (33.6 15.9 mo, hazard ratio [HR] 0.5, 95% confidence interval [CI]: 0.4-0.7, p < 0.001), subgroups candidate (36.1 17.2 HR CI: 0.001) (not reached 23.1 0.4, 0.2-0.7, 0.001). In multivariate analysis, associated improved (HR 0.6, 0.4-0.9, intention 0.02) 0.3, 0.1-0.6, 0.002). An (±LRT) NSCLC. Prospective randomized trial data are necessary identify most likely benefit from adding

Language: Английский

Citations

0
Oligometastatic NSCLC: Current Perspectives and Future Challenges DOI Creative Commons
Sara Torresan, José Luís Costa,

Carol Zanchetta

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(2), P. 75 - 75

Published: Jan. 29, 2025

Oligometastatic non-small cell lung cancer (NSCLC) represents a separate entity with different biology and prognosis compared to stage IV NSCLC. Challenges range from the very definition of oligometastatic disease timing techniques local treatments, their benefit in prolonging patient survival. Most international consensus guidelines agree on need for shared criteria, such as appropriate stadiation even tissue biopsy if needed, order select patients that could really personalised strategies. Multidisciplinary evaluation is crucial define every lesion amenable radical treatment, which appears be most important criterion across guidelines. A distinction must made depending time oligo-disease detection, separating de novo oligorecurrence, oligoprogression oligoresidual disease. These entities imply prognosis, treatment strategies consequently tailored. Locoregional approaches are therefore often contemplated ensure best outcome patient. In non-oncogene-addicted disease, advent immune checkpoint blockers (ICBs) allows physicians take into consideration consolidative but timing, technique subsequent systemic remain open issues. oncogene-addicted NSCLC, treatments nowadays preferably reserved cases oligoprogression, new, more potent drugs might challenge that. this review, we summarised current knowledge, consensuses data retrospective prospective trials, aim shedding some light topic emphasising unmet clinical need.

Language: Английский

Citations

0
Evaluation of the Esmo-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer with Radiosurgery DOI
James B. Yu,

Benjamin W. Corn,

S. Qureshi

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Recommandations de la prise en charge des CBNPC oligométastatiques DOI
Alice Mogenet, Laurent Greillier, Pascale Tomasini

et al.

Bulletin du Cancer, Journal Year: 2025, Volume and Issue: 112(3), P. 3S95 - 3S99

Published: March 1, 2025

Language: Английский

Citations

0